SCYNEXIS, Inc. (SCYX) CEO Marco Taglietti on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/12/22
SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific MeetingGlobeNewsWire • 05/10/22
SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific MeetingGlobeNewsWire • 05/04/22
SCYNEXIS Presents Data Analyses Showing Ibrexafungerp's Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious DiseasesGlobeNewsWire • 04/27/22
SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and WarrantsGlobeNewsWire • 04/26/22
SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and WarrantsGlobeNewsWire • 04/22/22
SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal InfectionsGlobeNewsWire • 04/22/22
SCYNEXIS to Present Positive Interim Data from Ongoing FURI and CARES Studies at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Being Held April 23-26 in Lisbon, PortugalGlobeNewsWire • 04/20/22
SCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME® (ibrexafungerp tablets), Providing Access to an Estimated 93 Million Commercially-Insured LivesGlobeNewsWire • 04/19/22
SCYNEXIS, Inc. (SCYX) CEO Marco Taglietti on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/29/22
SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/29/22
SCYNEXIS to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business UpdateGlobeNewsWire • 03/24/22
SCYNEXIS Named to Fast Company's 2022 Top 50 List of the World's Most Innovative CompaniesGlobeNewsWire • 03/08/22
BREXAFEMME® (ibrexafungerp tablets) Added to Major National Formulary, Providing Access for Millions More Commercially Insured PatientsGlobeNewsWire • 12/20/21
European Medicines Agency Grants Orphan Medicinal Product Designation for SCYNEXIS' Innovative Antifungal Ibrexafungerp for the Indication of Invasive CandidiasisGlobeNewsWire • 12/15/21